Cesare Gridelli
- Oncology top 0.1%
- Lung Cancer Research Studies 199
- Colorectal Cancer Treatments and Studies 64
- Cancer Immunotherapy and Biomarkers 42
- Cancer Treatment and Pharmacology 35
- Pulmonary and Respiratory Medicine top 0.1%
- Lung Cancer Treatments and Mutations 304
- Lung Cancer Diagnosis and Treatment 128
- Cancer Research top 0.5%
- Cancer Genomics and Diagnostics 30
- Geriatrics and Gerontology top 1%
- Molecular Biology top 2%
- Cancer therapeutics and mechanisms 51
Cesare Gridelli
407 papers receiving 12.3k citations
Hit Papers
Peers
Comparison fields: 5 of 147
- Oncology 7.7k
- Pulmonary and Respiratory Medicine 7.3k
- Cancer Research 1.7k
- Geriatrics and Gerontology 286
- Molecular Biology 3.1k
Countries citing papers authored by Cesare Gridelli
This map shows the geographic impact of Cesare Gridelli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cesare Gridelli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cesare Gridelli more than expected).
Fields of papers citing papers by Cesare Gridelli
This network shows the impact of papers produced by Cesare Gridelli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cesare Gridelli. The network helps show where Cesare Gridelli may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Cesare Gridelli, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2024 | 0 | |
| 3 | 2023 | 2 | |
| 4 | 2020 | 6 | |
| 5 | 2019 | 2 | |
| 6 | 2019 | 15 | |
| 7 | 2018 | 9 | |
| 8 | 2018 | 13 | |
| 9 | 2017 | 8 | |
| 10 | Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trialsbreakdown → | 2015 | 330 |
| 11 | 2014 | 18 | |
| 12 | 2013 | 40 | |
| 13 | 2011 | 13 | |
| 14 | Biomarker Associations With Survival for Refractory NSCLC Patients Receiving Erlotinib +/- Sunitinib in a Randomized Phase 2 Trial | 2010 | 1 |
| 15 | 2009 | 57 | |
| 16 | 2007 | 17 | |
| 17 | 2004 | 143 | |
| 18 | Complete response of severe symptomatic bone marrow metastases from heavily pretreated breast cancer with a 3-weekly trastuzumab schedule. A clinical case. | 2004 | 3 |
| 19 | Oral cytotoxic drugs. | 2002 | 3 |
| 20 | 2002 | 5 |
About Cesare Gridelli
Cesare Gridelli is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Hepatology and Molecular Biology, having authored 413 papers that have together received 12.6k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (304 papers), Lung Cancer Research Studies (199 papers), Lung Cancer Diagnosis and Treatment (128 papers), Colorectal Cancer Treatments and Studies (64 papers), Cancer therapeutics and mechanisms (51 papers), Cancer Immunotherapy and Biomarkers (42 papers), Cancer Treatment and Pharmacology (35 papers) and Cancer Genomics and Diagnostics (30 papers). The work is most often cited by research in Oncology (7.7k citations), Pulmonary and Respiratory Medicine (7.3k citations), Cancer Research (1.7k citations), Geriatrics and Gerontology (286 citations) and Molecular Biology (3.1k citations). Cesare Gridelli has collaborated with scholars based in Italy, United States and Spain. Frequent co-authors include Antônio Rossi, Paolo Maione, Massimo Di Maïo, Enriqueta Felip, Fortunato Ciardiello, Filippo de Marinis, Solange Peters, Ciro Gallo, Francesco Perrone and Alex A. Adjei. Their work appears in journals such as Lung Cancer, Annals of Oncology, Journal of Clinical Oncology, Clinical Lung Cancer and Journal of Thoracic Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.